Anthropometric Measurements as Predictors of Low Birth Weight Among Tanzanian Neonates: A Hospital-Based Study
November 7, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Cystografin
Synonyms :
diatrizoate
Class :
Ionic/High Osmolality, Contrast Media, Iodinated Contrast Media
Brand Name :
Cystografin
Synonyms :
diatrizoate
Class :
Ionic/High Osmolality, Contrast Media, Iodinated Contrast Media
Dosage Forms & StrengthsÂ
uretral solutionÂ
18% (dilute)Â
30%Â
Dosage Forms & StrengthsÂ
uretral solutionÂ
18% (dilute)Â
30%Â
Refer to the adult dosing regimenÂ
alpha-1 agonists decrease the efficacy of other alpha-1 agonists
may decrease the therapeutic effect when combined with iobenguane radiopharmaceutical products
may decrease the therapeutic effect when combined with iobenguane radiopharmaceutical products
may decrease the therapeutic effect when combined with iobenguane radiopharmaceutical products
may decrease the therapeutic effect when combined with iobenguane radiopharmaceutical products
may decrease the therapeutic effect when combined with iobenguane radiopharmaceutical products
may decrease the therapeutic effect when combined with Iobenguane Radiopharmaceutical Products
may decrease the therapeutic effect when combined with Iobenguane Radiopharmaceutical Products
may decrease the therapeutic effect when combined with Iobenguane Radiopharmaceutical Products
may decrease the therapeutic effect when combined with Iobenguane Radiopharmaceutical Products
may decrease the therapeutic effect when combined with Iobenguane Radiopharmaceutical Products
may decrease the therapeutic effect of amphetamines
metyrosine: they may decrease the therapeutic effect of iobenguane radiopharmaceutical products
may decrease the therapeutic effect when combined with iobenguane radiopharmaceutical products
may decrease the therapeutic effect when combined with iobenguane radiopharmaceutical products
may decrease the therapeutic effect when combined with iobenguane radiopharmaceutical products
may decrease the therapeutic effect when combined with iobenguane radiopharmaceutical products
may decrease the therapeutic effect when combined with iobenguane radiopharmaceutical products
may decrease the therapeutic effect when combined with iobenguane radiopharmaceutical products
may decrease the therapeutic effect when combined with iobenguane radiopharmaceutical products
may decrease the therapeutic effect when combined with iobenguane radiopharmaceutical products
may decrease the therapeutic effect when combined with iobenguane radiopharmaceutical products
may decrease the therapeutic effect when combined with iobenguane radiopharmaceutical products
may decrease the therapeutic effect when combined with Iobenguane Radiopharmaceutical Products
may decrease the therapeutic effect when combined with Iobenguane Radiopharmaceutical Products
may decrease the therapeutic effect when combined with Iobenguane Radiopharmaceutical Products
may decrease the therapeutic effect when combined with Iobenguane Radiopharmaceutical Products
may decrease the therapeutic effect when combined with Iobenguane Radiopharmaceutical Products
may decrease the therapeutic effect when combined with radiopharmaceutical iobenguane products
may decrease the therapeutic effect when combined with radiopharmaceutical iobenguane products
may decrease the therapeutic effect when combined with radiopharmaceutical iobenguane products
may decrease the therapeutic effect when combined with radiopharmaceutical iobenguane products
may decrease the therapeutic effect when combined with radiopharmaceutical iobenguane products
may decrease the therapeutic effect when combined with radiopharmaceutical iobenguane products
may decrease the therapeutic effect when combined with radiopharmaceutical iobenguane products
may decrease the therapeutic effect when combined with radiopharmaceutical iobenguane products
may decrease the therapeutic effect when combined with radiopharmaceutical iobenguane products
may decrease the therapeutic effect when combined with radiopharmaceutical iobenguane products
diatrizoate leads to a reduction in the rate of excretion of nitric oxide, which leads to an increased level of serum
may decrease the therapeutic effect when combined with radiopharmaceutical iobenguane products
may decrease the therapeutic effect when combined with radiopharmaceutical iobenguane products
may decrease the therapeutic effect when combined with radiopharmaceutical iobenguane products
may decrease the therapeutic effect when combined with radiopharmaceutical iobenguane products
may decrease the therapeutic effect when combined with radiopharmaceutical iobenguane products
diatrizoate might lead to a reduction in the rate of excretion of telavancin, potentially leading to elevated levels of serum
Actions and spectrum:Â
diatrizoate is a radiopaque contrast agent used for diagnostic imaging procedures such as X-rays, computed tomography (CT) scans, and angiograms. It works by enhancing the contrast between different tissues and organs in the body, which makes it easier for healthcare providers to identify and diagnose abnormalities or diseases.
diatrizoate is primarily used to visualize the gastrointestinal tract, urinary tract, and blood vessels. It is also used in certain medical procedures, such as hysterosalpingography, to help diagnose fertility problems in women.Â
Frequency not definedÂ
Transient thyroid suppression or hypothyrodismÂ
With drug intravasationÂ
Contraindication/Caution:Â
Contraindication:Â
diatrizoate is contraindicated in patients with known hypersensitivity to the drug or to any of its components. It is also contraindicated in patients with severe renal impairment, severe congestive heart failure, and pulmonary edema. Additionally, diatrizoate should not be used in patients with conditions that may lead to an increased risk of fluid and electrolyte imbalance, such as dehydration, anuria, or severe liver disease. It should be used under caution in patients with a history of thyroid disease or hyperuricemia, as well as in pregnant and lactating women. Â
Caution:Â
Comorbidities:Â
Patients with these comorbidities may require special precautions or adjustments to the dosage of diatrizoate to minimize the risk of adverse effects.Â
Pregnancy consideration: US FDA pregnancy category: CÂ
Lactation: It is not known if diatrizoate is excreted in human milk. Â
Pregnancy category:Â
Pharmacology:Â
diatrizoate works by selectively absorbing X-rays to create a contrast between the targeted area and surrounding tissues.Â
When administered intravenously, diatrizoate distributes rapidly throughout the extracellular fluid space. It is then excreted primarily by the kidneys and, to a lesser extent, by the liver. The peak plasma concentration occurs within 5 minutes after intravenous injection, and the half-life of elimination is approximately 2 hours.Â
diatrizoate is classified as an iodinated contrast agent, and it has a high atomic number, allowing it to absorb X-rays more effectively than surrounding tissues. This property results in an increased radiodensity of the targeted area, improving the visibility of the tissue or organ being imaged. Â
Pharmacodynamics:Â
When diatrizoate is injected into the bloodstream, it interacts with the body’s tissues and fluids, causing the X-rays or other imaging modalities to be absorbed or scattered differently. This results in enhanced contrast and improved visualization of the area being examined. The contrast enhancement occurs due to the differential attenuation of X-rays by different tissues and structures in the body, allowing for improved differentiation between them on the images.Â
The onset of action of diatrizoate is rapid, typically within minutes of injection. Its duration of action is also relatively short, with the contrast effect typically lasting for several hours before being excreted from the body. Â
Pharmacokinetics:Â
AbsorptionÂ
Oral diatrizoate is poorly absorbed from the gastrointestinal tract. However, rectal diatrizoate can be absorbed into the bloodstream. Injectable diatrizoate is administered intravascularly and rapidly distributes throughout the body.Â
DistributionÂ
After intravascular injection, diatrizoate distributes rapidly and extensively throughout the body. It primarily accumulates in the blood, liver, spleen, and kidneys. The degree of distribution is influenced by several factors such as the dose, the rate of injection, the cardiac output, and the degree of vascular permeability.Â
MetabolismÂ
diatrizoate is not metabolized in the body and is excreted unchanged in the urine.Â
Elimination and excretionÂ
diatrizoate is rapidly excreted from the body primarily through the kidneys by glomerular filtration. Its elimination half-life is approximately 2 hours in patients with normal renal function. In patients with impaired renal function, the half-life can be prolonged.Â
Administration:Â
diatrizoate is usually administered intravenously or through oral or rectal route, depending on the indication for use. The injection should be given slowly to avoid adverse reactions, and the patient should be monitored closely during and after administration. Oral diatrizoate should be taken with plenty of water and the patient should remain well hydrated during the procedure.
The rectal route of administration involves the use of enemas, which should be administered according to the healthcare provider’s instructions. It is important to follow the recommended dose and administration schedule to avoid adverse effects and ensure optimal diagnostic efficacy.Â
Patient information leafletÂ
Generic Name: diatrizoateÂ
Pronounced: [dye-a-TRYE-zoe-ate]Â Â
Why do we use diatrizoate?Â
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
